Document:

Exhibit 10367

		

			Exhibit 10.367

		

		

			 

		

		
			SUMMARY OF NON-EMPLOYEE DIRECTOR COMPENSATION
		

		
			 
		

		
			The Board of Directors approved revisions to the supplemental cash retainers paid to committee members and committee chairs on December 9, 2015.  Effective January 1, 2016, non-employee director compensation was as follows:
		

		
			Cash Retainers
		

		
			Each non-employee director receives an annual cash retainer in the amount of $100,000.
		

		
			The Chair of the Audit Committee and the Risk Committee receive a supplemental annual cash retainer of $35,000 and each other member of the Audit Committee and Risk Committee receives  a supplemental annual cash retainer of $15,000.  The Chair of the Compensation Committee receives a supplemental cash retainer of $30,000, and the Chair of the Nominating and Governance Committee receives  a supplemental annual cash retainer of $25,000.  Each other member of the Compensation Committee and Nominating and Corporate Governance Committee receives a supplemental annual cash retainer of $10,000.  There are no fees paid for attendance at board or committee meetings.
		

		
			The board retains the discretion to establish special committees in the future and to pay a special retainer to the Chair and the members of any such special committee.
		

		
			Equity Grants
		

		
			Each non-employee director receives an annual equity grant under the 2013 Stock Incentive Plan with an aggregate value of $140,000.  The equity grants  are 50 percent in stock options and 50 percent in restricted shares.  Equity grants vest 25% on each of the first and second anniversaries of the date of grant and the remaining 50% on the third anniversary of the date of grant.
		

		
			In the event a new non-employee director is elected to the board during the year, a pro-rata retainer amount with the same ratio between cash retainers and equity grants is granted to that individual.amag_EX_10_11

		
			Exhibit 10.11
		

		
			AMAG PHARMACEUTICALS, INC.
		

		
			RESTRICTED STOCK UNIT AWARD AGREEMENT
FOR COMPANY EMPLOYEES
		

		
			 
		

			
					
						Name of Grantee:

					
					
						 

					
					
						 

				
	
					
						No. of Restricted Stock Units:

					
					
						 

					
					
						 

					
					
						 

				
	
					
						Grant Date:

					
					
						 

					
					
						 

					
					
						 

				

		
			Pursuant to the AMAG Pharmaceuticals, Inc. Third Amended and Restated 2007 Equity Incentive Plan/Lumara Health Inc. Amended and Restated 2013 Incentive Compensation Plan, as amended through the date hereof (the “Plan”), AMAG Pharmaceuticals, Inc. (the “Company”) hereby grants an award of the number of Restricted Stock Units listed above (an “Award”) to the Grantee named above.  Each Restricted Stock Unit shall relate to one share of Common Stock, par value $0.01 per share (the “Stock”) of the Company.  
		

		
			1.Restrictions on Transfer of Award.  This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of until (i) the Restricted Stock Units have vested as provided in Section 2 of this Agreement and (ii) shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this Agreement.
		

		
			2.Vesting of Restricted Stock Units.  The restrictions and conditions of Section 1 of this Agreement shall lapse on the Vesting Date or Dates specified in the following schedule so long as the Grantee remains in a Business Relationship (as defined in Section 3 below) on such Dates.  If a series of Vesting Dates is specified, then the restrictions and conditions in Section 1 shall lapse only with respect to the number of Restricted Stock Units specified as vested on such date.
		

			
					
						Incremental Number of
Restricted Stock Units Vested

					
					
						    

					
					
						Vesting Date

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						_____________ (___%)

					
					
						 

					
					
						____________

				
	
					
						_____________ (___%)

					
					
						 

					
					
						____________

				
	
					
						_____________ (___%)

					
					
						 

					
					
						____________

				

		
			The Administrator may at any time accelerate the vesting schedule specified in this Section 2.
		

		
			3.Termination of Business Relationship.  
		

		
			(a)If the Grantee’s Business Relationship terminates for any reason (including death or disability) prior to the satisfaction of the vesting conditions set forth in Section 2 above, any Restricted Stock Units that have not vested as of such date shall automatically and without notice terminate and be forfeited, and neither the Grantee nor any of his or her successors, heirs, assigns, or personal representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units.  
		

		
			
		

		 

		

			Page 1 of 4

		

 

		
			(b) “Business Relationship” means service to the Company or any of its Subsidiaries, or its or their successors, in the capacity of an employee, officer, director, consultant or advisor.  For purposes hereof, a Business Relationship shall not be considered as having terminated during any military leave, sick leave, or other leave of absence if approved in writing by the Company and if such written approval, or applicable law, contractually obligates the Company to continue the Business Relationship of the Grantee after the approved period of absence (an “Approved Leave of Absence”). In the event of an Approved Leave of Absence, vesting of Restricted Stock Units shall be suspended (and all subsequent vesting dates shall be postponed by the length of the period of the Approved Leave of Absence) unless otherwise provided in the Company’s written approval of the leave of absence. For purposes hereof, a Business Relationship shall include a consulting arrangement between the Grantee and the Company that immediately follows termination of employment, but only if so stated in a written consulting agreement executed by the Company.
		

		
			4.Issuance of Shares of Stock.  As soon as practicable following each Vesting Date, the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate number of Restricted Stock Units that have vested pursuant to Section 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares; provided, however, if a Vesting Date shall occur during either a regularly scheduled or special “blackout period” wherein the Grantee is precluded from selling shares of Stock, the receipt of the corresponding underlying shares issuable with respect to such Vesting Date pursuant to this Agreement shall be deferred until after the expiration of such blackout period unless such underlying shares are covered by a previously established Company-approved 10b5-1 plan of the Grantee, in which case the underlying shares shall be issued in accordance with the terms of such 10b5-1 plan; provided, however, that the issuance of such shares shall not be deferred any later than the later of: (a) December 31st of the calendar year in which such vesting occurs, or (b) the 15th day of the third calendar month following such vesting date, and if such settlement occurs while either a regularly scheduled or special “blackout period” is still in effect, neither the Company nor the Grantee may sell any shares issued in settlement thereof to satisfy any tax or withholding obligations except in compliance with the Company’s Statement of Company Policy Regarding Insider Training and other applicable requirements and laws.
		

		
			5.Incorporation of Plan.  Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan.  Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.
		

		
			6.Tax Withholding.  The Grantee shall, not later than the date as of which the receipt of this Award becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Company for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event.  The Company shall have the authority to cause the minimum required tax withholding obligation to be satisfied, in whole or in part, by withholding from shares of Stock to be issued to the Grantee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the minimum withholding amount due. 
		

		
			7.Section 409A of the Code.  This Agreement shall be interpreted in such a manner that all provisions relating to the settlement of the Award are exempt from the requirements of Section 409A of the Code as “short-term deferrals” as described in Section 409A of the Code.
		

		
			8.No Obligation to Continue Business Relationship.  Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Grantee’s Business Relationship, and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Business Relationship of the Grantee at any time.
		

		
			
		

		 

		

			Page 2 of 4

		

 

		
			9.Integration.  This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter.
		

		
			10.Data Privacy Consent.  In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the “Relevant Companies”) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the “Relevant Information”).  By entering into this Agreement, the Grantee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate.  The Grantee shall have access to, and the right to change, the Relevant Information.  Relevant Information will only be used in accordance with applicable law.
		

		
			11.Notices.  Notices hereunder shall be mailed or delivered to the Company at its principal place of business to the attention of the Company’s Treasurer and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.
		

		
			 
		

		
			[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
		

		
			
		

		
			

		 

		

			Page 3 of 4

		

 

SIGNATURE PAGE TO AMAG PHARMACEUTICALS, INC.
		

		
			RESTRICTED STOCK UNIT AWARD AGREEMENT
		

			
					
						 

					
					
						AMAG PHARMACEUTICALS, INC.

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						By:

					
					
						 

				
	
					
						 

					
					
						 

					
					
						Name:

					
					
						William K. Heiden

				
	
					
						 

					
					
						 

					
					
						Title:

					
					
						Chief Executive Officer

				

		
			 
		

		
			The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned, and the undersigned acknowledges receipt of a copy of this entire Agreement, a copy of the Plan, and a copy of the Plan’s related prospectus.  Electronic acceptance of this Agreement pursuant to the Company’s instructions to the Grantee (including through an online acceptance process) is acceptable.
		

			
					
						Dated:

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						Grantee’s Signature

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						Grantee’s name and address:

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

				

		
			 
		

		 

		

			Page 4 of 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}]]